Bristol-Myers Squibb Company (NYSE:BMY) went down by -1.84% from its latest closing price compared to the recent 1-year high of $68.34. The company’s stock price has collected -1.29% of loss in the last five trading sessions. Press Release reported on 10/02/20 that Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients
Is It Worth Investing in Bristol-Myers Squibb Company (NYSE :BMY) Right Now?
Plus, the 36-month beta value for BMY is at 0.64. Opinions of the stock are interesting as 10 analysts out of 18 who provided ratings for Bristol-Myers Squibb Company declared the stock was a “buy,” while 3 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $73.54, which is $14.9 above the current price. BMY currently public float of 2.25B and currently shorts hold a 0.64% ratio of that float. Today, the average trading volume of BMY was 9.86M shares.
BMY’s Market Performance
BMY stocks went down by -1.29% for the week, with a monthly drop of -4.68% and a quarterly performance of -2.44%, while its annual performance rate touched 18.51%. The volatility ratio for the week stands at 1.90% while the volatility levels for the past 30 days are set at 2.08% for Bristol-Myers Squibb Company. The simple moving average for the period of the last 20 days is -0.91% for BMY stocks with a simple moving average of -2.99% for the last 200 days.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Berenberg repeating the rating for BMY by listing it as a “Buy.” The predicted price for BMY in the upcoming period, according to Berenberg is $73 based on the research report published on September 29th of the current year 2020.
Raymond James, on the other hand, stated in their research note that they expect to see BMY reach a price target of $75. The rating they have provided for BMY stocks is “Outperform” according to the report published on July 28th, 2020.
Morgan Stanley gave a rating of “Overweight” to BMY, setting the target price at $64 in the report published on April 02nd of the current year.
BMY Trading at -2.91% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.08% of loss for the given period.
Volatility was left at 2.08%, however, over the last 30 days, the volatility rate increased by 1.90%, as shares sank -2.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.92% lower at present.
During the last 5 trading sessions, BMY fell by -1.29%, which changed the moving average for the period of 200-days by -8.41% in comparison to the 20-day moving average, which settled at $59.19. In addition, Bristol-Myers Squibb Company saw -8.52% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BMY starting from Caforio Giovanni, who sale 39,840 shares at the price of $62.70 back on Aug 31. After this action, Caforio Giovanni now owns 445,584 shares of Bristol-Myers Squibb Company, valued at $2,497,968 using the latest closing price.
Eid Joseph, the SVP,Head Glob. Medical Affairs of Bristol-Myers Squibb Company, sale 5,327 shares at $64.00 during a trade that took place back on Aug 17, which means that Eid Joseph is holding 2,534 shares at $340,928 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- +24.63 for the present operating margin
- +65.98 for the gross margin
The net margin for Bristol-Myers Squibb Company stands at +13.15. The total capital return value is set at 10.67, while invested capital returns managed to touch 5.96. Equity return is now at value -1.30, with -0.50 for asset returns.
Based on Bristol-Myers Squibb Company (BMY), the company’s capital structure generated 92.13 points at debt to equity in total, while total debt to capital is 47.95. Total debt to assets is 36.58, with long-term debt to equity ratio resting at 85.39. Finally, the long-term debt to capital ratio is 44.44.
Currently, EBITDA for the company is 3.58B with total debt to EBITDA at 5.67. When we switch over and look at the enterprise to sales, we see a ratio of 5.44, with the company’s debt to enterprise value settled at 0.33. The receivables turnover for the company is 3.68 and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.